Latest Australian Securities News

Dart Mining NL’s DTMOC securities have been suspended from trading by the ASX due to non-compliance with key listing rules, raising questions about the company’s regulatory standing.

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.

Trading in New World Resources Limited shares has been suspended following compulsory acquisition notices issued by Kinterra Capital, signaling a major ownership shift.

The ASX has formally warned Truscott Mining Corporation that its current operations may not meet listing requirements, giving the company six months to demonstrate compliance or face suspension.

Trading in Aspermont Limited shares has resumed following the ASX's immediate lifting of the suspension after the company released a key announcement.

Cannindah Resources Limited has voluntarily suspended its shares from trading as it prepares to announce a significant capital raising. The suspension is set to last until the announcement or the resumption of trading on August 22.

MIXI Australia has extended its takeover offer for PointsBet shares to 29 August 2025 and announced a conditional increase in the offer price from $1.25 to $1.30 per share, aiming to secure at least 90% ownership.

Lincoln Minerals Limited’s LMLO securities have been suspended from ASX quotation due to non-compliance with listing rules, raising questions about the company’s regulatory standing.

Astron Corporation Limited is set to redomicile from Hong Kong to Australia through a scheme of arrangement, creating a new Australian parent company, Aus NewCo. This move aims to align the corporate structure with its Australian assets and simplify shareholder voting.

Ideagen has completed its acquisition of Envirosuite through a scheme of arrangement, with shareholders receiving A$0.09 per share. Envirosuite shares will be officially delisted from the ASX on 21 August 2025.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

Whitefield Income Limited has reported a $7.8 million net profit in its first seven months as an ASX-listed company, alongside steady monthly dividends annualised at 8%. The company’s portfolio outperformed its benchmark, signaling a promising start post-IPO.